Dabigatran etexilate (DE)

DRUG2 trials

Sponsors

Boehringer Ingelheim, Pfizer

Conditions

HealthyVenous Thromboembolism

Phase 1

A Drug-Drug Interaction Study to Estimate the Effect of PF-07081532 on the Pharmacokinetics of Dabigatran and Rosuvastatin in Overweight or Obese Adult Participants

TerminatedNCT05788328

Start: 2023-03-27End: 2023-09-11Updated: 2024-11-15

Unknown Phase

A Study in Europe Based on Medical Records That Looks at the Safety of Dabigatran in Children Below 2 Years of Age Who Have Had a Blood Clot and Are at Risk of Developing Another Blood Clot

WithdrawnNCT05536791

Boehringer IngelheimVenous Thromboembolism

Start: 2022-11-24End: 2024-10-01Updated: 2024-06-26

Related Papers

Assessment of the Drug-Drug Interaction Potential of Lotiglipron (PF-07081532) with Midazolam, Omeprazole, Dabigatran, Rosuvastatin, and the Oral Contraceptives Levonorgestrel and Ethinyl Estradiol.

PubMed2026-05-01

Evaluation of an oral small‐molecule glucagon‐like peptide‐1 receptor agonist, lotiglipron, for type 2 diabetes and obesity: A dose‐ranging, phase 2, randomized, placebo‐controlled study

Diabetes Obesity and Metabolism2024-10-1617 citations